(Q40910489)

24 September 2017

title

Antineoplastic drugs that interfere with iron metabolism in cancer cells (English)

1 reference

24 September 2017

J F Head

1

1 reference

24 September 2017

F Wang

series ordinal

2

1 reference

24 September 2017

R L Elliott

series ordinal

3

1 reference

24 September 2017

publication date

1 January 1997

1 reference

Advances in Enzyme Regulation

24 September 2017

published in

1 reference

24 September 2017

volume

37

1 reference

24 September 2017

page(s)

147-169

1 reference

Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Differential effects of gallium nitrate on proliferation of brain tumor cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Alteration of DNA synthesis in human brain tumor cells by gallium nitrate in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Antineoplastic effects of gallium nitrate on human medulloblastoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Prevention of gallium toxicity by hyperhydration in treatment of medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Gallium nitrate in advanced bladdercarcinoma: Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

A Phase II Trial of Gallium Nitrate (NSC #15200) in Previously Treated Ovarian Carcinoma A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Phase II evaluation of gallium nitrate by continuous infusion in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid HL60 and lymphoid CCRF-CEM leukaemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Recent advances in cancer research: drug targeting without the use of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Characterization of the anti-cancer activity of transferrin-adriamycin conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Kinetics of internalization and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line, K562.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2571%2896%2900010-6

7 January 2021

10.1016/S0065-2571(96)00010-6

Identifiers

DOI

1 reference

24 September 2017

1 reference